Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Barrick Gold Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Barrick Gold Corp trades at $36.46 (market cap $61.25B). The key difference: Barrick Gold Corp is the larger of the two by market cap, and Barrick Gold Corp pays a 1.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | B | |
|---|---|---|
Market Cap | $39.89B | $61.25B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $52.97 |
52-Week Low | $278.09 | $20.73 |
Enterprise Value | $38.15B | $58.85B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Barrick Mining (B) trades at $36.68, down 0.41% on the day, with a bearish technical signal but strong fundamentals. The company reported robust 2025 results with revenue of $16.96B and net income of $4.99B, beating earnings estimates in recent quarters. Analyst consensus is strongly bullish with a $51.80 price target, though technical indicators show near-term weakness with support at $36.
The stock presents a value opportunity with a low P/E of 10.07 and strong cash flow growth, but faces headwinds from gold price volatility and bearish momentum. Upside potential exists if Q2 2026 earnings meet or exceed expectations, while risks include commodity price swings and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
